580 related articles for article (PubMed ID: 23324275)
1. Frequency of T-cell FoxP3⁺ Treg and CD4⁺/CD8⁺ PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon.
Ma H; Zhang HH; Wei L
Chin Med J (Engl); 2013 Jan; 126(2):267-73. PubMed ID: 23324275
[TBL] [Abstract][Full Text] [Related]
2. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
Ma H; Yang RF; Wei L
J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
[TBL] [Abstract][Full Text] [Related]
3. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
4. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B.
Li CZ; Hu JJ; Xue JY; Yin W; Liu YY; Fan WH; Xu H; Liang XS
World J Gastroenterol; 2014 Jul; 20(28):9486-96. PubMed ID: 25071343
[TBL] [Abstract][Full Text] [Related]
5. [Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].
Xie DY; Lin BL; Chen FJ; Deng H; Chong YT; Zhang XH; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):646-50. PubMed ID: 20943073
[TBL] [Abstract][Full Text] [Related]
6. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
7. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.
Zhang M; Li G; Shang J; Pan C; Zhang M; Yin Z; Xie Q; Peng Y; Mao Q; Xiao X; Jiang Y; Luo K; Xu Y; Ding H; Fan W; Diego V; Pourkarim MR; De Clercq E; Wang G; Gong G
Hepatol Int; 2020 Mar; 14(2):212-224. PubMed ID: 32100261
[TBL] [Abstract][Full Text] [Related]
8. The reduction in CD8
Liu R; Chen Y; Guo J; Li M; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Zhang H; Xie Y
BMC Infect Dis; 2020 Aug; 20(1):590. PubMed ID: 32778058
[TBL] [Abstract][Full Text] [Related]
9. [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
Dong RQ; Zhou DF; Han R; Zhou JY; Zhao CY; Zhen Z
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):899-902. PubMed ID: 24636290
[TBL] [Abstract][Full Text] [Related]
10. HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b.
Ma H; Yang RF; Li XH; Jin Q; Wei L
Chin Med J (Engl); 2016 Sep; 129(18):2212-9. PubMed ID: 27625094
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
[TBL] [Abstract][Full Text] [Related]
14. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
15. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
[TBL] [Abstract][Full Text] [Related]
16. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
[TBL] [Abstract][Full Text] [Related]
17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
20. [Factors influencing the curative effect in patients with HBeAgpositive chronic hepatitis B treated with peg-interferon α-2a].
Chen J; Zheng Q; Jiang J; Zheng J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 37(7):714-9. PubMed ID: 22886227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
